Avanir's Generic Combo Successful in Alzheimer's Study
the Neurology Advisor take:
Avanir Pharmaceuticals says its generic combination drug, AVP-923, was successful in suppressing agitation in patients with Alzheimer’s disease in a phase II clinical trial.
The drug, which combines generic cough suppressant dextromethorphan and generic quinidine, used to control irregular heartbeats, is the same drug combo that the company used in its approval for Nuedexta as a treatment for uncontrolled outbursts of emotion seen in pseudobulbar effect.
In the 10-week, randomized, placebo-controlled clinical trial of AVP-923, significant reductions in agitation were observed by both the primary and secondary endpoints of the neuropsychiatric inventory (NPI). Reductions in agitation were observed in both stage 1 (p=0.0002) and stage 2 (p=0.021) of the Sequential Parallel Comparison study design.
Improvements in secondary endpoints included total NPI score (p=0.014), clinical global impression of change-agitation (p=0.0003) and measures of caregiver burden (p≤0.05). While AVP-923 was generally well-tolerated, the most common adverse reactions included falls, diarrhea and urinary tract infections.
Following the trial’s positive results, Avanir plans to request meetings with both the FDA and European Medicines Agency to discuss further use of dextromethorphan programs in clinical studies related to Alzheimer’s disease.
Still, there is some concern over the “new” drug, which actually combines two old ones. The FDA has been calling for more innovative therapies for the treatment of Alzheimer’s, and members of US Congress will likely balk if Avanir attempts to price the generic drug combo as a high-priced therapy.
Avanir skyrockets as its controversial generic combo claims a hit in PhII Alzheimer's study
Next Article in Neurodegenerative Diseases
Neurology Advisor Articles
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- Court Rules That U.S. Must Halt Sales of Pesticide Chlorpyrifos
- Both Abstinence and High Alcohol Use Linked to Dementia
- Therapeutic Plasma Exchange Effectively Improves Ambulation in Pediatric Transverse Myelitis
- TBI Linked to Increased Suicide Risk
- OnabotulinumtoxinA for Post-Stroke Spasticity: Treatment Strategies and Limitations